(RTTNews) - Phathom Pharmaceuticals (PHAT) announced the FDA's establishment of a public docket to solicit comment on legal and regulatory questions regarding certain issues raised by a filer of an abbreviated new drug application referencing VOQUEZNA tablets, BDR Pharmaceuticals